«

»

FDA approves 1st targeted HER2-low breast cancer therapy

The FDA approved Enhertu Aug. 6, the first targeted therapy for HER2-low breast cancer.

Read the full post at Becker's Hospital Review - Healthcare News
Vote This Post DownVote This Post Up (No Ratings Yet)
Explore the Archive